ERBB2 and neoplasm: In particular, more than one third of HER2-0 primary breast cancer patients exhibited a conversion towards HER2-low expression in the metastatic lesion, and more than 40% of patients with HER2-low expression in the primary tumor switched towards HER2-0 recurrent/stage IV breast cancer.